Update on carbonic anhydrase inhibitors: A patent review (2008 - 2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 8, 2012, Pages 903-915

  Aggarwal, Mayank ^a   McKenna, Robert ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

CA IX; Cancer; Carbonic anhydrase; Carbonic anhydrase inhibitor; Drug design; Glaucoma; Proton transfer

Indexed keywords

4 (4 METHYLPIPERAZIN 1 YLMETHYL) N [4 METHYL 3 (4 PYRIDIN 3 YL)PYRIMIDIN 2 YLAMINO]PHENYL]BENZAMIDE; 4 METHYL 3 [[4 (3 PYRIDINYL) 2 PYRIMIDINYL]AMINO] N [5 (4 METHYL 1H IMIDAZOL 1 YL) 3 (TRIFLUOROMETHYL)PHENYL]; ACETAZOLAMIDE; AGENTS ACTING ON THE EYE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX ANTIBODY; CARBONATE DEHYDRATASE IX INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DORZOLAMIDE; ENZYME ANTIBODY; ESZOPICLONE; ETHOXZOLAMIDE; IMATINIB; MACROGOL; METHAZOLAMIDE; MODAFINIL; NILOTINIB; POLYESTER; POLYMER; POLYSORBATE; SULFAMIDE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLPIDEM;

ALTITUDE DISEASE; BINDING AFFINITY; BIOCOMPATIBILITY; DEPRESSION; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; EPILEPSY; FATIGUE; GLAUCOMA; HEADACHE; HUMAN; IMPLANT; LENNOX GASTAUT SYNDROME; LIBIDO DISORDER; MALAISE; MEMBRANE PERMEABILITY; METALLIC TASTE; MYOPIA; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; OSTEOPOROSIS; PARESTHESIA; PATENT; PROTEIN FUNCTION; REVIEW; RNA INTERFERENCE; SIDE EFFECT; SLEEP APNEA SYNDROME; TASTE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DRUG DESIGN; HUMANS; LEGISLATION, DRUG; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864247302     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.707646     Document Type: Review

References (120)

1. Messerchmidt A, Bode W, Cygler M. Handbook of metalloproteins. John Wiley and Sons Ltd: West Sussex, England; 2004
2. Domsic JF, Avvaru BS, Kim CU, et al. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem 2008;283(45):30766-71
3. Scozzafava A, Mastrolorenzo A, Supuran CT. Carbonic anhydrase inhibitors and activators and their use in therapy. Expert Opin Ther Patents 2006;16(12):1627-64 (Pubitemid 46017244)
4. Supuran CT, Scozzafava A, Conway J. Carbonic anhydrase: Its inhibitors and activators. CRC Press: Boca Raton, Florida, USA; 2004
5. Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23(2):146-89 (Pubitemid 36241096)
6. Pastorekova S, Parkkila S, Pastorek J, et al. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004;19(3):199-229 (Pubitemid 39004275)
7. Chegwidden WR, Carter ND. The carbonic anhydrases: new horizons. Birkhauser: Birkhauser Verlag. Basel, Switzerland; 2000
8. Krishnamurthy VM, Kaufman GK, Urbach AR, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem. Rev 2008;108(3):946-1051 (Pubitemid 351577855)
9. Supuran CT, Winum J-Y, Wang B. Drug design of zinc-enzyme inhibitors: functional, structural, and disease applications. John Wiley & Sons: Hoboken, New Jersey, USA; 2009
10. Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. Nature 2008;452(7183):56-61 (Pubitemid 351355092)
11. Maren TH. Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol Rev 1967;47(4):595-781
12. Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors: Cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem 2007;15(23):7229-36 (Pubitemid 47539154)
13. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem 2004;47(5):1272-9 (Pubitemid 38229129)
14. Nishimori I, Vullo D, Innocenti A, et al. Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2005;48(24):7860-6
15. Nishimori I, Minakuchi T, Onishi S, et al. Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors. J Med Chem 2007;50(2):381-8 (Pubitemid 46147718)
16. Vullo D, Voipio J, Innocenti A, et al. Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2005;15(4):971-6 (Pubitemid 40458632)
17. Vullo D, Franchi M, Gallori E, et al. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett 2003;13(6):1005-9 (Pubitemid 36331787)
18. Vullo D, Innocenti A, Nishimori I, et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs? Bioorg Med Chem Lett 2005;15(4):963-9 (Pubitemid 40458631)
19. Nishimori I, Vullo D, Innocenti A, et al. Carbonic anhydrase inhibitors: Inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett 2005;15(17):3828-33 (Pubitemid 41095477)
20. Lehtonen J, Shen B, Vihinen M, et al. Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J Biol Chem 2004;279(4):2719-27 (Pubitemid 38114261)
21. Supuran CT, Ilies MA, Scozzafava A. Carbonic anhydrase inhibitors - part 29 1: Interaction of isozymes I, II and IV with benzolamide-like derivatives. Eur J Med Chem 1998;33(9):739-51 (Pubitemid 29161324)
22. Supuran CT, Scozzafava A, Ilies MA, et al. Carbonic anhydrase inhibitors: Synthesis of sulfonamides incorporating 2,4,6-trisubstituted- pyridiniumethylcarboxamido moieties possessing membrane-impermeability and in vivo selectivity for the membrane-bound (CA IV) versus the cytosolic (CA I and CA II) isozymes. J Enzym Inhib 2000;15(4):381-401 (Pubitemid 30433730)
23. Scozzafava A, Briganti F, Ilies MA, et al. Carbonic anhydrase inhibitors: Synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J Med Chem 2000;43(2):292-300 (Pubitemid 30078161)
24. Winum J-Y, Temperini C, El Cheikh K, et al. Carbonic anhydrase inhibitors: Clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem 2006;49:24:7024-31 (Pubitemid 44885990)
25. Saczewski F, Sławinski R, Kornicka A, et al. Carbonic anhydrase inhibitors. Inhibition of the cytosolic human isozymes I and II, and the transmembrane, tumor-associated isozymes IX and XII with substituted aromatic sulfonamides activatable in hypoxic tumors. Bioorg Med Chem Lett 2006;16(18):4846-51 (Pubitemid 44177775)
26. De Simone G, Vitale RM, Di Fiore A, et al. Carbonic anhydrase inhibitors: hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem 2006;49(18):5544-51 (Pubitemid 44373185)
27. Kohler K, Hillebrecht A, Schulze Wischeler J, et al. Saccharin inhibits carbonic anhydrases: Possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl 2007;46(40):7697-9 (Pubitemid 47557029)
28. Maupin CM, Castillo N, Taraphder S, et al. Chemical rescue of enzymes: Proton transfer in mutants of human carbonic anhydrase II. J Am Chem Soc 2011;133(16):6223-34
29. Lindskog S. Structure and mechanism of carbonic anhydrase. Pharmacol Ther 1997;74(1):1-20 (Pubitemid 27337350)
30. Silverman DN, McKenna R. Solvent-mediated proton transfer in catalysis by carbonic anhydrase. Acc Chem Res 2007;40(8):669-75
31. Roy A, Taraphder S. Identification of proton-transfer pathways in human carbonic anhydrase II. J Phys Chem B 2007;111(35):10563-76 (Pubitemid 47441861)
32. Tu CK, Silverman DN, Forsman C, et al. Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant. Biochemistry 1989;28(19):7913-18 (Pubitemid 19238127)
33. Fisher SZ, Maupin CM, Budayova-Spano M, et al. Atomic crystal and molecular dynamics simulation structures of human carbonic anhydrase II: Insights into the proton transfer mechanism. Biochemistry 2007;46(11):2930-7 (Pubitemid 46449117)
34. Alterio V, Vitale RM, Monti SM, et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc 2006;128(25):8329-35 (Pubitemid 43967776)
35. Thiry A, Dogne J-M, Masereel B, et al. Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci 2006;27(11):566-73 (Pubitemid 44574507)
36. Stams T, Nair SK, Okuyama T, et al. Crystal structure of the secretory form of membrane-associated human carbonic anhydrase IV at 2.8-A resolution. Proc Natl Acad Sci USA 1996;93(24):13589-94
37. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7(2):168-81 (Pubitemid 351194064)
38. Dubois L, Peeters S, Lieuwes NG, et al. Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol 2011;99(3):424-31
39. Cianchi F, Vinci MC, Supuran CT, et al. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010;334(3):710-19
40. Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19(1):87-112
41. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring? J Med Chem 1999;42(14):2641-50 (Pubitemid 29344304)
42. Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as anti-glaucoma agents. Curr Top Med Chem 2007;7(9):849-54 (Pubitemid 46825081)
43. Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors: Synthesis of water-soluble, aminoacyl/ dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem 1999;42(18):3690-700 (Pubitemid 29445102)
44. Ilies M, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors: Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg Med Chem 2000;8(8):2145-55 (Pubitemid 30612505)
45. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 2000;43(23):4542-51 (Pubitemid 32046879)
46. Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J Med Chem 2002;45(7):1466-76 (Pubitemid 34246110)
47. Matulis D, Virginija D, Matuliene J, et al. Benzimidazo[1,2-c][1,2,3] Thiadiazol-7-sulfonamides as inhibitors of carbonic anhydrase and the intermediates for production thereof. 2008
48. Parkkila S, Innocenti A, Kallio H, et al. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. Bioorg Med Chem Lett 2009;19(15):4102-6
49. Supuran CT, Parkkila S. Treatment of mammalian disorders mediated by alpha-carbonic anhydrase isoforms. 2010
50. Chang JN, Hughes PM, Devries GW. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems. 2011
51. Seal S, Patil SD, Haldar MK, et al. Functionalized nanoceria composition for ophthalmic treatment. 2011
52. Inoue J, Shah T. Ophthalmic composition. 2011
53. Liang S, Song C, Lin Z. Ophthalmic composition of carbonic anhydrase inhibitor. 2011
54. Liang S, Song C, Lin Z. Ophthalmic composition of heteroaryl sulfamoyl carboxylic ester carbonic anhydrase inhibitor. 2011
55. Shepard AR, Chatterton JE, Clark AF. RNAi-mediated inhibition of ocular hypertension targets. 2009
56. RNAi-mediated inhibition of ocular targets. 2009
57. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-5 (Pubitemid 29246458)
58. Semenza GL. Hypoxia and cancer. Cancer Metastasis Rev 2007;26(2):223-4 (Pubitemid 47101662)
59. Brahimi-Horn MC, Pouyssegur J. Oxygen, a source of life and stress. FEBS Lett 2007;581(19):3582-91 (Pubitemid 47081011)
60. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292(5516):468-72 (Pubitemid 32335942)
61. Hon W-C, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002;417(6892):975-8 (Pubitemid 34716877)
62. Dorai T, Sawczuk I, Pastorek J, et al. Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: Proposal of a unified hypothesis. Cancer Invest 2006;24(8):754-79 (Pubitemid 44949880)
63. Ord JJ, Agrawal S, Thamboo TP, et al. An investigation into the prognostic significance of necrosis and hypoxia in high grade and invasive bladder cancer. J Urol 2007;178(2):677-82 (Pubitemid 47030492)
64. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26(2):299-310 (Pubitemid 47101667)
65. Hutchison GJ, Valentine HR, Loncaster JA, et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: Correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004;10(24):8405-12 (Pubitemid 40053403)
66. Sung FL, Hui EP, Tao Q, et al. Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett 2007;253(1):74-88 (Pubitemid 46881199)
67. Koukourakis MI, Giatromanolaki A, Sivridis E, et al. Hypoxia-activated tumor pathways of angiogenesis and pH regulation independent of anemia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004;59(1):67-71 (Pubitemid 38501508)
68. Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89(1):2-7 (Pubitemid 36897927)
69. Hussain SA, Ganesan R, Reynolds G, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer 2007;96(1):104-9 (Pubitemid 46094646)
70. Trastour C, Benizri E, Ettore F, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Int J Cancer 2007;120(7):1451-8 (Pubitemid 46355379)
71. Swinson DEB, Jones JL, Richardson D, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 2003;21(3):473-82 (Pubitemid 46613490)
72. Di Fiore A, Pedone C, D'Ambrosio K, et al. Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. Bioorg Med Chem Lett 2006;16(2):437-42 (Pubitemid 41680643)
73. Abbate F, Coetzee A, Casini A, et al. Carbonic anhydrase inhibitors: x-ray crystallographic structure of the adduct of human isozyme II with the antipsychotic drug sulpiride. Bioorg Med Chem Lett 2004;14(2):337-41 (Pubitemid 38045118)
74. Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577(3):439-45 (Pubitemid 39535327)
75. Cecchi A, Hulikova A, Pastorek J, et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J Med Chem 2005;48(15):4834-41 (Pubitemid 41033126)
76. Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: Stacking with Phe131 determines active site binding region of inhibitors as exemplified by the x-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48(18):5721-7 (Pubitemid 41298346)
77. Abbate F, Winum J-Y, Potter BVL, et al. Carbonic anhydrase inhibitors: x-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg Med Chem Lett 2004;14(1):231-4 (Pubitemid 38016213)
78. Winum J-Y, Vullo D, Casini A, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic isozymes I and II and transmembrane, tumor-associated isozyme IX with sulfamates including EMATE also acting as steroid sulfatase inhibitors. J Med Chem 2003;46(11):2197-204 (Pubitemid 36583498)
79. Winum J-Y, Vullo D, Casini A, et al. Carbonic anhydrase inhibitors: Inhibition of transmembrane, tumor-associated isozyme IX, and cytosolic isozymes I and II with aliphatic sulfamates. J Med Chem 2003;46(25):5471-7 (Pubitemid 37490379)
80. Garaj V, Puccetti L, Fasolis G, et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumorassociated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating 1,2,4-triazine moieties. Bioorg Med Chem Lett 2004;14(21):5427-33 (Pubitemid 39348939)
81. Innocenti A, Casini A, Alcaro MC, et al. Carbonic anhydrase inhibitors: The first on-resin screening of a 4-sulfamoylphenylthiourea library. J Med Chem 2004;47(21):5224-9 (Pubitemid 39314919)
82. Cecchi A, Winum J-Y, Innocenti A, et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides derived from 4-isothiocyanato- benzolamide. Bioorg Med Chem Lett 2004;14(23):5775-80 (Pubitemid 39421518)
83. Winum J-Y, Pastorekova S, Jakubickova L, et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett 2005;15(3):579-84
84. Winum J-Y, Innocenti A, Nasr J, et al. Carbonic anhydrase inhibitors: Synthesis and inhibition of cytosolic/tumorassociated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxysulfamides-a new zinc-binding function in the design of inhibitors. Bioorg Med Chem Lett 2005;15(9):2353-8
85. Winum J-Y, Cecchi A, Montero J-L, et al. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/ tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: Toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg Med Chem Lett 2005;15(13):3302-6 (Pubitemid 40799079)
86. Thiry A, Ledecq M, Cecchi A, et al. Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem 2006;49(9):2743-9
87. Pastorekova S, Casini A, Scozzafava A, et al. Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX. Bioorg Med Chem Lett 2004;14(4):869-73 (Pubitemid 38167605)
88. Vullo D, Scozzafava A, Pastorekova S, et al. Carbonic anhydrase inhibitors: Inhibition of the tumor-associated isozyme IX with fluorine-containing sulfonamides. The first subnanomolar CA IX inhibitor discovered. Bioorg. Med. Chem. Lett. 2004;14(9):2351-6 (Pubitemid 38481419)
89. Casey JR, Morgan PE, Vullo D, et al. Carbonic anhydrase inhibitors. Design of selective, membrane-impermeant inhibitors targeting the human tumor-associated isozyme IX. J Med Chem 2004;47(9):2337-47 (Pubitemid 38478857)
90. Supuran CT, Casini A, Mastrolorenzo A, et al. COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev Med Chem 2004;4(6):625-32 (Pubitemid 38961227)
91. Park MY, Lim KM, Shin SO, et al. Dual inhibition of cyclooxygenase-2 and carbonic anhydrase. 2010
92. Supuran CT, Scozzafava A. Sulfonamide Derivatives Having Carbonic Anhydrase Inhibiting Activity and their Use as Therapeutic and Diagnostic Agents. 2008
93. Ebbesen P, Supuran CT, Scozzafava A, et al. Carbonic anhydrase inhibitors. 2011
94. Supuran CT, Dedhar S, McDonald P, et al. Novel sulfonamide compounds for inhibition of metastatic tumor growth. 2010
95. Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. Chem Commun (Camb.) 2010;46(44):8371-3
96. Supuran CT, Scozzafava A, Pastorekova S, et al. CA IX-specific inhibitors. 2008
97. Wong J, Winter J, Lalehzadeh G, et al. Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen Mn/CA IX. 2009
98. Riihonen R, Supuran CT, Parkkila S, et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone 2007;40(4):1021-31 (Pubitemid 46386547)
99. Pierce WM, Waite LC. Bone targeted inhibitors of carbonic anhydrase. 1997
100. Wilson LF, Tam P, Najarian T, et al. Treatment of obstructive sleep apnea syndrome with a combination of a caronic anhydrase inhibitor and an additional active agent. 2011
101. Dawson TL. Malassezia globosa and restricta: Breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc 2007;12(2): 15-19
102. Guillot J, Hadina S, Gueho E. The genus Malassezia: Old facts and new concepts. Parassitologia. 2008;50(1-2):77-9
103. Galuppi R, Tampieri MP. Epidemiology and variability of Malassezia spp. Parassitologia. 2008;50(1-2):73-6
104. Hewitson L, Supuran CT. Carbonic anhydrase inhibitors for treating dandruff and related disorders. 2010
105. Kannan KK, Ramanadham M, Jones TA. Structure, refinement, and function of carbonic anhydrase isozymes: Refinement of human carbonic anhydrase I. Ann NY Acad Sci 1984;429:49-60 (Pubitemid 14085829)
106. Avvaru BS, Kim CU, Sippel KH, et al. A short, strong hydrogen bond in the active site of human carbonic anhydrase II. Biochemistry 2010;49(2):249-51
107. Duda DM, Tu C, Fisher SZ, et al. Human carbonic anhydrase III: Structural and kinetic study of catalysis and proton transfer. Biochemistry 2005;44(30):10046-53 (Pubitemid 41076800)
108. Boriack-Sjodin PA, Heck RW, Laipis PJ, et al. Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: Implications for catalytic proton transfer and inhibitor design. Proc Natl Acad Sci USA 1995;92(24):10949-53
109. Alterio V, Hilvo M, Di Fiore A, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proc Natl Acad Sci USA 2009;106(38):16233-8
110. Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA 2001;98(17):9545-50 (Pubitemid 32769340)
111. Whittington DA, Grubb JH, Waheed A, et al. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: Implications for selective inhibition of membrane-associated isozymes. J Biol Chem 2004;279(8):7223-8 (Pubitemid 38248870)
112. Domsic JF, Williams W, Fisher SZ, et al. Structural and kinetic study of the extended active site for proton transfer in human carbonic anhydrase II. Biochemistry 2010;49(30):6394-9
113. Ghosh AK, Thompson WJ, Fitzgerald PM, et al. Structure-based design of HIV-1 protease inhibitors: Replacement of two amides and a 10 pi-aromatic system by a fused bis-tetrahydrofuran. J Med Chem 1994;37(16):2506-8 (Pubitemid 24276776)
114. Amari S, Aizawa M, Zhang J, et al. VISCANA: Visualized cluster analysis of protein-ligand interaction based on the ab initio fragment molecular orbital method for virtual ligand screening. J Chem Inf Model 2006;46(1):221-30 (Pubitemid 43282117)
115. Greer J, Erickson JW, Baldwin JJ, et al. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem 1994;37(8):1035-54 (Pubitemid 24145364)
116. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16(4):295-305
117. Oprea TI, Davis AM, Teague SJ, et al. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci 2001;41(5):1308-15
118. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1(1):55-68
119. Eriksson AE, Kylsten PM, Jones TA, et al. Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: A pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins 1988;4(4): 283-93 (Pubitemid 19094187)
120. Hen N, Bialer M, Yagen B, et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. J Med Chem 2011;54(11):3977-81